303 results on '"Grivas, P."'
Search Results
2. Cross-cultural adaptation, reliability and validity of the Greek version of the Spinal Appearance Questionnaire (SAQ) in patients with adolescent idiopathic scoliosis
3. Mediterranean diet and exercise are associated with better disease control in psoriatic arthritis
4. Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study
5. Rib index is a strong surrogate of scoliometric reading in idiopathic scoliosis
6. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer
7. Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
8. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
9. Managing Temporomandibular Joint Osteoarthritis by Dental Stem Cell Secretome
10. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
11. Two cases of SMA syndrome after neurosurgical injury to the frontal aslant tract
12. Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study
13. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
14. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
15. Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma
16. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
17. General Medical Practitioners’ Preferences in Referring Patients with Head and Neck Disorders; A Cross-Sectional Evaluative Study in Greece
18. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
19. NECTIN4 RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100.
20. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced penile squamous cell carcinoma (CAPSCC).
21. Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.
22. Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.
23. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC).
24. Molecular subtypes, NECTIN4/HER2 expression, and clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): Exploratory analyses from JAVELIN Bladder 100 and the Tempus database.
25. TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study.
26. Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.
27. MTAP loss in primary kidney tumors: A comprehensive genomic profiling study.
28. Clinically advanced prostate cancer (CAPC) in extremely young men: A genomic landscape study.
29. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor
30. The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection
31. COVID-19 vaccination and breakthrough infections in patients with cancer
32. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
33. Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium
34. Bartha-K61 vaccine protects nursery pigs against challenge with novel european and asian strains of suid herpesvirus 1
35. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
36. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
37. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
38. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
39. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
40. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.
41. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
42. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
43. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study
44. Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal
45. Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board
46. Establishing consensus on the best practice guidelines for the use of bracing in adolescent idiopathic scoliosis
47. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma
48. Transition technologies towards 6G networks
49. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
50. A systematic review of natural language processing applied to radiology reports
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.